D-0519-2019 Class III Terminated

Recalled by Jubilant Cadista Pharmaceuticals, Inc. — Salisbury, MD

FDA drug recall D-0519-2019 was initiated by Jubilant Cadista Pharmaceuticals, Inc. on Feb 28, 2019 and is designated Class III. Reason for recall: Failed Dissolution Specifications; 9-monthstability timepoint The recall status is terminated (terminated Mar 5, 2020). Affected quantity: a) 3,072 bottles; b) 2,688 bottles.

Recall details

Product Type
Drugs
Report Date
Mar 13, 2019
Initiation Date
Feb 28, 2019
Termination Date
Mar 5, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
a) 3,072 bottles; b) 2,688 bottles

Product description

BuPROPion Hydrochloride Extended-Release Tablets, USP (XL) 150 mg, a) 30 count (NDC 59746- 758-30) & b) 90 count (NDC 59746-758-90) bottles, Rx only, Manufactured b Jubilant Generis Ltd, Roorkee, India, Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD

Reason for recall

Failed Dissolution Specifications; 9-monthstability timepoint

Distribution pattern

Product was distributed to one customer who may have further distributed the product.

Code information

a) BR117002C, exp. date 11/2019; b) BR117003B and BR117004B, exp. date 11/2019

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0519-2019
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0519-2019. Report a data issue: hello@regdatalab.com.